Compounded Medications — Everything You Need to Know
A 503(a) compounding pharmacy. A licensed physician. A Certificate of Analysis available on request. This is the resource hub for understanding compounded semaglutide and tirzepatide as we dispense them — what makes them different from brand-name, why we use them, what the FDA changed in 2026, and where to start.
The cluster — start here
Compounded vs. Brand-Name
Side-by-side comparison of compounded semaglutide/tirzepatide vs. Wegovy, Ozempic, Mounjaro, and Zepbound. Pricing, regulatory pathway, sourcing, when each is the right answer.
Why We Choose to Compound
Five clinical reasons plus the economic reality. The honest answer to "why don't you just dispense Wegovy?"
GLP-1 Side-by-Side
Semaglutide vs. tirzepatide vs. retatrutide. Mechanism, weight loss, side effects, dosing, and FDA approval status — without marketing.
503(a) vs. 503(b) Pharmacies
The two compounding pathways under U.S. law. Why the distinction matters for patient safety and which pathway NHWL operates under.
FDA in 2026 — Where Things Stand
Verified timeline of FDA actions on compounded semaglutide and tirzepatide through May 2026. What the April 30 503B Bulks proposal actually changes.
Compounded vs. Ozempic/Wegovy (Deep)
Deeper analysis of compounded semaglutide vs. brand-name Ozempic and Wegovy. Strictly factual; legal-careful regulatory framing.
Trump–Novo Deal Explained
The November 2025 pricing arrangement that brought branded Ozempic to ~$245/month for eligible Medicare/Medicaid patients. Comparison with compounded options.
Amazon Ozempic Same-Day
The May 7, 2026 Amazon Pharmacy launch and oral Wegovy 25mg pill. Honest comparison with NHWL's bundled physician-supervised model.
What "compounded" means in our practice
When we say "compounded" at New Hope Weight Loss, we mean exactly one thing: a preparation made by a state-licensed 503(a) pharmacy for an individual patient with a valid prescription written by Dr. Sharma after a documented clinical evaluation. The compound includes a clinically meaningful difference from any FDA-approved finished drug — typically a different dose, a different concentration, or an additional ingredient (most commonly B12) that creates a distinct preparation tailored to the patient.
That's the regulatory pathway. The practical outcome: medication that lets us titrate dose with precision the brand-name pen can't, with B12 or lipotropic support layered in if appropriate, sourced from a pharmacy whose name we share with you and whose Certificate of Analysis we can hand over.
The transparency commitments we make
- Pharmacy name on the invoice. Ask, and it's written down. We work only with state-licensed 503(a) pharmacies in California.
- Certificate of Analysis on request. Per batch, per prescription. The COA documents potency and sterility.
- Active ingredient sourcing. APIs come from FDA-registered manufacturing facilities. The pharmacy verifies sourcing for every batch.
- Sterility standards. 503(a) compounding follows USP 797 (sterile compounding) and USP 800 (hazardous drug handling) standards.
- Physician oversight. Every prescription is written after Dr. Sharma reviews medical history, contraindications, and goals. No exceptions.
What we don't do (the things that get other compounders in trouble)
- We don't dispense without a documented physician evaluation.
- We don't claim equivalence to brand-name medications. The FDA's regulatory rule about "duplicate" preparations is the legal standard; we follow it.
- We don't use offshore peptide sources, gray-market suppliers, or anything labeled "research peptide" / "not for human use."
- We don't compound for patients with absolute contraindications (history of medullary thyroid carcinoma, MEN-2, active pancreatitis, severe gastroparesis, current pregnancy or breastfeeding).
- We don't pretend the regulatory framework doesn't matter. It does. The FDA's April 30, 2026 503B proposal didn't affect us, but we monitor every FDA action.
When brand-name Wegovy / Ozempic / Mounjaro / Zepbound is the right answer
We're a compounded-medication clinic, and we still recommend brand-name when it fits:
- Your insurance covers Wegovy, Zepbound, Ozempic, or Mounjaro for your indication and your out-of-pocket is comparable.
- You qualify for the Medicare/Medicaid Trump–Novo deal pricing at ~$245/month.
- You're enrolled in a clinical trial of a specific brand-name product.
- You have a documented allergy or sensitivity to a compounding excipient.
- You travel internationally frequently and prefer commercial packaging documentation.
We tell patients this directly during the consultation. We're not in the business of selling compounded therapy to patients for whom branded fits better.
Frequently asked questions
What is a compounded medication?
A medication made by a licensed pharmacy for an individual patient with a valid physician prescription. Compounding has been part of U.S. medicine for over a century. Section 503(a) of the Federal Food, Drug, and Cosmetic Act governs traditional patient-specific compounding.
Are compounded medications safe?
Quality depends on the specific compounding pharmacy. Reputable state-licensed 503(a) pharmacies follow USP 797/800 sterility standards, source APIs from FDA-registered facilities, and provide a Certificate of Analysis on request. NHWL works only with state-licensed 503(a) pharmacies. Quality drops sharply with offshore peptide vendors — avoid those.
What is a Certificate of Analysis?
A document from the compounding pharmacy verifying the potency, sterility, and purity of a specific batch. NHWL provides the COA on request for any prescription.
Did the FDA ban compounded GLP-1 in 2026?
No. The April 30, 2026 proposal to remove semaglutide and tirzepatide from the 503B Bulks List affects only 503(b) outsourcing facilities. 503(a) patient-specific compounding remains legal. NHWL operates exclusively under the 503(a) pathway.
Why does NHWL use compounded medications?
Five clinical reasons (individualized titration, B12/lipotropic add-ons, supplier control, supply continuity, total-cost transparency) plus the economic reality that makes the protocol sustainable for uninsured patients. See Why We Choose to Compound for the full clinical rationale.
This page is informational only and not medical advice. Speak with a licensed physician before starting any GLP-1 therapy. Individual results vary. New Hope Weight Loss dispenses compounded semaglutide and compounded tirzepatide via state-licensed 503(a) compounding pharmacies in California for individual patients with valid prescriptions. We do not dispense Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Compounded medications are not FDA-approved finished products. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with, endorsed by, or sponsored by these companies.